Latest news with #Everolimus
Associated Press
21-04-2025
- Business
- Associated Press
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion
FORT LAUDERDALE, FL / ACCESS Newswire / April 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched Everolimus in the Canadian generic prescription drugs market. Everolimus is a generic equivalent of the brand name Afinitor®. Everolimus is indicated for the treatment of (i) advanced renal cell carcinoma, (ii) breast cancer in post-menopausal women with advanced HER2-negative genotype, (iii) progressive well or moderately differentiated neuroendocrine tumors of pancreatic, gastrointestinal or lung origin, and (iv) subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Nora Pharma's Everolimus is available in strengths of 2.5 mg, 5 mg, and 10 mg and comes in blister packs of 30 tablets. According to DATAINTELO, the global Everolimus market was valued at $2.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.1%, reaching around $4.8 billion by 2032. The Canadian segment of the global market is approximately 2.2% and increasing at a compound annual growth rate (CAGR) of 6.4% (IQVIA Pharmafocus 2027). 'Our presence in the industry is propelled by a relentless pursuit of progress,' said Dr. Steve Slilaty, CEO of Sunshine Biopharma. 'Through continued investment in cutting-edge technologies, breakthrough research, and strategic partnerships, we are advancing solutions that create lasting impact for patients,' he added. About Sunshine Biopharma Inc. Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and more than 15 additional drugs scheduled to be launched in remainder of 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: All registered trademarks are the property of their respective owners. Safe Harbor Forward-Looking Statements This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the 'Company') that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings. For more information, please contact: Camille Sebaaly, CFO Direct Line: 514-814-0464 [email protected] SOURCE: Sunshine Biopharma Inc. press release
Globe and Mail
15-04-2025
- Health
- Globe and Mail
Carcinoid Tumor Syndrome Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight
DelveInsight " Carcinoid Tumor Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Carcinoid Tumor Syndrome, historical and forecasted epidemiology as well as the Carcinoid Tumor Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover which therapies are expected to grab the Carcinoid Tumor Syndrome Market Share @ Carcinoid Tumor Syndrome Market Outlook Key Takeaways from the Carcinoid Tumor Syndrome Market Report The increase in Carcinoid Tumor Syndrome Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM. As per DelveInsight analysis, the Carcinoid Tumor Syndrome Market is anticipated to witness growth at a considerable CAGR. The leading Carcinoid Tumor Syndrome Companies such as Novartis Pharmaceuticals, Crinetics Pharmaceuticals Inc., Lexicon Pharmaceuticals, Ipsen, Camurus AB, Delcath Systems Inc., INSYS Therapeutics Inc., and others. Promising Carcinoid Tumor Syndrome Pipeline Therapies such as Octreotide, Everolimus, Pasireotide (SOM230), Telotristat etiprate, Lanreotide, Isolated Perfusion, Fentanyl sublingual spray and others. Stay ahead in the Carcinoid Tumor Syndrome Therapeutics Market with DelveInsight's Strategic Report @ Carcinoid Tumor Syndrome Treatment Market Size Carcinoid Tumor Syndrome Epidemiology Segmentation in the 7MM The epidemiology section of Carcinoid Tumor Syndrome offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions. Download the report to understand which factors are driving Carcinoid Tumor Syndrome Epidemiology trends @ Carcinoid Tumor Syndrome Prevalence Carcinoid Tumor Syndrome Drugs Market The Carcinoid Tumor Syndrome Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Carcinoid Tumor Syndrome signaling in Carcinoid Tumor Syndrome are likely to uncover new therapeutic targets and further expand treatment options for patients. Carcinoid Tumor Syndrome Treatment Market Landscape The Carcinoid Tumor Syndrome treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Carcinoid Tumor Syndrome has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies. To learn more about Carcinoid Tumor Syndrome treatment guidelines, visit @ Carcinoid Tumor Syndrome Treatment Market Landscape Carcinoid Tumor Syndrome Market Outlook The report's outlook on the Carcinoid Tumor Syndrome market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Carcinoid Tumor Syndrome therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Carcinoid Tumor Syndrome drug and late-stage pipeline therapy. Carcinoid Tumor Syndrome Drugs Uptake The drug chapter of the Carcinoid Tumor Syndrome report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Carcinoid Tumor Syndrome. Major Carcinoid Tumor Syndrome Companies Novartis Pharmaceuticals, Crinetics Pharmaceuticals Inc., Lexicon Pharmaceuticals, Ipsen, Camurus AB, Delcath Systems Inc., INSYS Therapeutics Inc., and others. Learn more about the FDA-approved drugs for Carcinoid Tumor Syndrome @ Drugs for Carcinoid Tumor Syndrome Treatment Scope of the Carcinoid Tumor Syndrome Market Report • Coverage- 7MM • Study Period- 2019-2032 • Carcinoid Tumor Syndrome Companies- Novartis Pharmaceuticals, Crinetics Pharmaceuticals Inc., Lexicon Pharmaceuticals, Ipsen, Camurus AB, Delcath Systems Inc., INSYS Therapeutics Inc., and others. • Carcinoid Tumor Syndrome Pipeline Therapies- Octreotide, Everolimus, Pasireotide (SOM230), Telotristat etiprate, Lanreotide, Isolated Perfusion, Fentanyl sublingual spray and others • Carcinoid Tumor Syndrome Market Dynamics: Carcinoid Tumor Syndrome Market Drivers and Barriers • Carcinoid Tumor Syndrome Market Access and Reimbursement, Unmet Needs and Future Perspectives Table of Content 1. Key Insights 2. Carcinoid Tumor Syndrome Executive Summary 3. Carcinoid Tumor Syndrome Competitive Intelligence Analysis 4. Carcinoid Tumor Syndrome: Market Overview at a Glance 5. Carcinoid Tumor Syndrome: Disease Background and Overview 6. Patient Journey 7. Carcinoid Tumor Syndrome Epidemiology and Patient Population 8. Treatment Algorithm, Current Treatment, and Medical Practices 9. Carcinoid Tumor Syndrome Unmet Needs 10. Key Endpoints of Carcinoid Tumor Syndrome Treatment 11. Carcinoid Tumor Syndrome Marketed Products 12. Carcinoid Tumor Syndrome Emerging Therapies 13. Carcinoid Tumor Syndrome: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Carcinoid Tumor Syndrome Market Outlook 16. Access and Reimbursement Overview of Carcinoid Tumor Syndrome 17. KOL Views 18. Carcinoid Tumor Syndrome Market Drivers 19. Carcinoid Tumor Syndrome Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
07-02-2025
- Business
- Yahoo
Pharma company to close Plymouth facility, lay off 58 workers
A pharmaceutical company is closing one of its Twin Cities facilities, resulting in dozens of workers being laid off later this year. Drug-maker Upsher-Smith confirmed in a WARN notice to the Minnesota Department of Employment and Economic Development (DEED) that it is closing its plant at 14905 23rd Avenue North. The company, which was bought by Taiwan-based Bora Pharmaceuticals in a $210 million deal last year, is keeping its facility at 6701 Evenstad Dr. N. in Maple Grove. The move will result in 58 employees being laid off, some of whom will be at the Maple Grove plant. Some staff from the Plymouth facility will be moved over to Maple Grove. Upsher-Smith says the Plymouth plant will close on April 1, with the layoffs happening in two or three waves ending on July 31. Upsher-Smith makes a series of generic drugs including the anticonvulsant Vigabatrin, cancer medication Everolimus, and Topiramate, which can be used to treat migraines and seizures. The company was founded in 1919 by England-native Frederick Alfred Upsher Smith, who launched a laboratory in downtown Minneapolis. It was bought by Ken Evenstad in 1969 and was owned by his family for almost 50 years before it was sold amid a family feud to Japan-based Sawai Pharmaceutical in 2017. In a statement to the Star Tribune, Upsher-Smith said the Plymouth closure represents a "strategic realignment to optimize global operations and better serve our customers."
